Literature DB >> 20463406

Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons.

Maria Manczak1, Peizhong Mao, Marcus J Calkins, Anda Cornea, Arubala P Reddy, Michael P Murphy, Hazel H Szeto, Byung Park, P Hemachandra Reddy.   

Abstract

The purpose of our study was to investigate the effects of the mitochondria-targeted antioxidants, MitoQ and SS31, and the anti-aging agent resveratrol on neurons from a mouse model (Tg2576 line) of Alzheimer's disease (AD) and on mouse neuroblastoma (N2a) cells incubated with the amyloid-beta (Abeta) peptide. Using electron and confocal microscopy, gene expression analysis, and biochemical methods, we studied mitochondrial structure and function and neurite outgrowth in N2a cells treated with MitoQ, SS31, and resveratrol, and then incubated with Abeta. In N2a cells only incubated with the Abeta, we found increased expressions of mitochondrial fission genes and decreased expression of fusion genes and also decreased expression of peroxiredoxins. Electron microscopy of the N2a cells incubated with Abeta revealed a significantly increased number of mitochondria, indicating that Abeta fragments mitochondria. Biochemical analysis revealed that function is defective in mitochondria. Neurite outgrowth was significantly decreased in Abeta-incubated N2a cells, indicating that Abeta affects neurite outgrowth. However, in N2a cells treated with MitoQ, SS31, and resveratrol, and then incubated with Abeta, abnormal expression of peroxiredoxins and mitochondrial structural genes were prevented and mitochondrial function was normal; intact mitochondria were present and neurite outgrowth was significantly increased. In primary neurons from amyloid-beta precursor protein transgenic mice that were treated with MitoQ and SS31, neurite outgrowth was significantly increased and cyclophilin D expression was significantly decreased. These findings suggest that MitoQ and SS31 prevent Abeta toxicity, which would warrant the study of MitoQ and SS31 as potential drugs to treat patients with AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463406      PMCID: PMC3072711          DOI: 10.3233/JAD-2010-100564

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  67 in total

1.  Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease.

Authors:  Heng Du; Lan Guo; Fang Fang; Doris Chen; Alexander A Sosunov; Guy M McKhann; Yilin Yan; Chunyu Wang; Hong Zhang; Jeffery D Molkentin; Frank J Gunn-Moore; Jean Paul Vonsattel; Ottavio Arancio; John Xi Chen; Shi Du Yan
Journal:  Nat Med       Date:  2008-09-21       Impact factor: 53.440

2.  Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients.

Authors:  Xinglong Wang; Bo Su; Hisashi Fujioka; Xiongwei Zhu
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

3.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

Review 4.  PGC-1alpha: a key regulator of energy metabolism.

Authors:  Huiyun Liang; Walter F Ward
Journal:  Adv Physiol Educ       Date:  2006-12       Impact factor: 2.288

5.  Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.

Authors:  Virginie Rhein; Xiaomin Song; Andreas Wiesner; Lars M Ittner; Ginette Baysang; Fides Meier; Laurence Ozmen; Horst Bluethmann; Stefan Dröse; Ulrich Brandt; Egemen Savaskan; Christian Czech; Jürgen Götz; Anne Eckert
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

6.  Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

Authors:  Lichuan Yang; Kesheng Zhao; Noel Y Calingasan; Guoxiong Luo; Hazel H Szeto; M Flint Beal
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

Review 7.  The role of FoxO in the regulation of metabolism.

Authors:  D N Gross; A P J van den Heuvel; M J Birnbaum
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

Review 8.  Targeting antioxidants to mitochondria by conjugation to lipophilic cations.

Authors:  Michael P Murphy; Robin A J Smith
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 9.  Coupling of the NMDA receptor to neuroprotective and neurodestructive events.

Authors:  Giles E Hardingham
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

10.  Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology.

Authors:  John H T Power; Sana Asad; Tim K Chataway; Fariba Chegini; James Manavis; James A Temlett; Poul H Jensen; Peter C Blumbergs; Wei-Ping Gai
Journal:  Acta Neuropathol       Date:  2008-04-02       Impact factor: 17.088

View more
  189 in total

1.  Upregulation of heme oxygenase-1 by acteoside through ERK and PI3 K/Akt pathway confer neuroprotection against beta-amyloid-induced neurotoxicity.

Authors:  Hong-Quan Wang; Yu-Xia Xu; Cui-Qing Zhu
Journal:  Neurotox Res       Date:  2011-12-07       Impact factor: 3.911

Review 2.  Somatic mutations in aging, cancer and neurodegeneration.

Authors:  Scott R Kennedy; Lawrence A Loeb; Alan J Herr
Journal:  Mech Ageing Dev       Date:  2011-11-03       Impact factor: 5.432

Review 3.  Role of mitochondrial homeostasis and dynamics in Alzheimer's disease.

Authors:  J Eva Selfridge; Lezi E; Jianghua Lu; Russell H Swerdlow
Journal:  Neurobiol Dis       Date:  2012-01-10       Impact factor: 5.996

Review 4.  Synaptic mitochondrial pathology in Alzheimer's disease.

Authors:  Heng Du; Lan Guo; Shirley ShiDu Yan
Journal:  Antioxid Redox Signal       Date:  2011-12-15       Impact factor: 8.401

Review 5.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

6.  Sphingosine kinase-1 protects differentiated N2a cells against beta-amyloid25-35-induced neurotoxicity via the mitochondrial pathway.

Authors:  Yang Yang; Min Wang; Bingjie Lv; Rong Ma; Jing Hu; Yaoyan Dun; Shenggang Sun; Gang Li
Journal:  Neurochem Res       Date:  2014-03-30       Impact factor: 3.996

Review 7.  Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.

Authors:  Thuy Trang Nguyen; Tuong Kha Vo; Giau Van Vo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Mitochondrial morphology-emerging role in bioenergetics.

Authors:  Chad A Galloway; Hakjoo Lee; Yisang Yoon
Journal:  Free Radic Biol Med       Date:  2012-09-29       Impact factor: 7.376

9.  Epoxyeicosatrienoic acids pretreatment improves amyloid β-induced mitochondrial dysfunction in cultured rat hippocampal astrocytes.

Authors:  Pallabi Sarkar; Ivan Zaja; Martin Bienengraeber; Kevin R Rarick; Maia Terashvili; Scott Canfield; John R Falck; David R Harder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-27       Impact factor: 4.733

Review 10.  Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.

Authors:  Lan Guo; Jing Tian; Heng Du
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.